Agents Useful for Treating Obesity, Diabetes and Related Disorders

Abstract

Researchers at the University of California, Davis have developed a method for treating or effecting prophylaxis of impaired insulin sensitivity, glucose tolerance, obesity and metabolic syndrome.

Full Description

Metabolic syndrome, a term describing a cluster of interrelated common clinical conditions, including obesity, insulin resistance, glucose intolerance, hypertension and dyslipidemia, is a severe and increasing health problem world-wide. Obesity and type 2 diabetes, both categorized within metabolic syndrome, are commonly comorbid metabolic diseases with obesity increasing the risk of developing type 2 diabetes by roughly ten-fold.

Researchers at the University of California, Davis have developed a method for treating or effecting prophylaxis of impaired insulin sensitivity, glucose tolerance, obesity and metabolic syndrome through administering an effective regime of idebenone and/or idebenone analogs, and re-establish sensitivity to insulin (anti-diabetes), mitigate corticosterone-induced insulin-resistance (anti-diabetes) and increase lipid oxidation (anti-obesity).

Applications

• Treatment or effecting prophylaxis of impaired insulin sensitivity, glucose tolerance, obesity or metabolic syndrome
• Inhibiting the development of type 2 diabetes or metabolic syndrome
• Treatment for non-alcoholic steatohepatitis (NASH)

Features/Benefits

• Compounds may provide an effective or complimentary treatment for insulin sensitivity
• Compounds may provide a treatment for non-alcoholic steatohepatitis (NASH)
• Compounds may compliment current diabetes therapies

Patent Status